Strategic Report AstraZeneca at a glance We are a global, innovation-driven biopharmaceutical business.
Financial summary $25.7 billion $8.4 billion $5.05 Sales down 6% at CER to $25,711 million Core operating profit down 23% at CER Core EPS for the full year decreased by $27,973 million in 2012 to$8,390 million $11,159 million in 2012 23% at CER to $5.05 $6.83 in 2012 $3.0 billion $3.7 billion $2.04 Net cash shareholder distributions Reported operating profit down 51% at CER Reported EPS for the full year decreased decreased by 49% to $2,979 million, partly to $3,712 million $8,148 million in 2012 by 55% at CER to $2.04 $4.95 in 2012 as a result of the cessation of the share repurchase programme $5,871 million net cash shareholder distributions including Restated for new Core definition as detailed on page 224.
$2,206 million net share repurchases in 2012 Restated for new Core definition and adoption of IAS 19 2011 as detailed on pages 136 and 224.
Restated on adoption of IAS 19 2011 as detailed on page 136.
Our proposition to investors AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from Pure-play innovation discovery, earlyand late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.
Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease CVMD : Oncology: and Respiratory, Inflammation and Autoimmunity RIA.
We are also active A focused, combined with in the Infection, Neuroscience and Gastrointestinal ING disease areas.
on-market with a distinctive disciplined We operate in more than 100 countries and our innovative medicines portfolio in three R&D platform capital are used by millions of patients worldwide.
core therapy and a growing allocation and areas and late-stage a commitment We want to be valued as a source of great medicines and trusted a strong pipeline to a progressive as a company that delivers business success responsibly.
committed to operating with integrity and high ethical standards presence across all our activities.
We push the boundaries of science to deliver life-changing medicines.
Our 10 leading medicines by sales value are: Cardiovascular and Metabolic disease Oncology More people die annually from cardiovascular diseases than from any Cancer is a leading cause of death worldwide and accounted for other cause an estimated 17.3 million people in 2008 representing 8.2million deaths in 2012.
Cancer medicines represented 12% of 30%of all global deaths.
Worldwide, 347 million people have diabetes.
WHO data 2 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information A global science-led company 51,500 1,300 2,800 employees worldwide employees in Russia employees in Japan 2.5% 5.5% 17,900 employees in Europe excluding Russia 11,200 34.8% employees in North America 8,000 21.7% employees in China 15.5% 3,100 2,100 5,100 employees in Central employees in employees in Asia Pacific and South America Middle East and Africa excluding China, Japan and Russia 6.0% 4.1% 9.9% 9,000 29,600 8,700 employees work in R&D employees work in Sales and Marketing employees work in Supply and Manufacturing All figures are approximate.
Respiratory, Inflammation and Autoimmunity Other leading medicines Some 235 million people suffer from asthma and an estimated 64 million people had COPD in 2004.
RIA medicines represented 18% of our sales in 2013 Pulmicort Symbicort Nexium Seroquel XR Synagis for asthma and COPD for asthma and COPD for acid-reflux for schizophrenia, bipolar for RSV, a respiratory disorder and major infection in infants depressive disorder 2011: $892m 2011: $3,148m 2011: $4,429m 2011: $1,490m 2011: $975m 2012: $866m 2012: $3,194m 2012: $3,944m 2012: $1,509m 2012: $1,038m 2013 2013 2013 2013 2013 $867m $3,483m $3,872 $1,337m $1,060m 1% 10% 0% -12% 2% AstraZeneca Annual Report and Form 20-F Information 2013 3 Strategic Report | AstraZeneca at a glance Financial overview Sales Core operating profit Core earnings per $m -6% $m -22% Ordinary Share $ -23% 13 25,711 13 8,390 13 5.05 12 6.83 12 27,973 12 11,159 13,932 11 7.68 11 33,591 11 Net cash flow from Reported operating profit Reported earnings per operating activities $m $m -51% Ordinary Share $ -55% 13 7,400 13 3,712 13 2.04 12 6,948 12 8,148 12 4.95 11 7,821 11 12,795 11 7.29 Operational overview Achieve Scientific Return to Growth Be a Great Place Leadership to Work 99 pipeline projects 6% reduction in revenue To drive accountability and improve including 85 in clinical development Revenue fell by 9% in the US, decision making, we made our and 14 either approved, launched 9% inEurope and 10% in Established organisational structure flatter.
Revenue rose by 8% in percent of employees are now within Emerging Markets six management steps of the CEO, 11 NMEs in Phase III of development compared to 40% of employees within or under regulatory review $2.2bn loss of exclusivity reduction six steps in 2012 almost double compared with 2012 Some $2.2 billion of revenue decline and achieving our 2016 target volume was related to loss of exclusivity on A pulse survey showed 84% almost three years ahead of schedule brands such as Arimidex, Atacand, employee belief in our strategy, in line Crestor, Nexium and Seroquel IR with the pharmaceutical sector norm 4 NME progressions to Phase III benralizumab, selumetinib, olaparib $1.2bn revenue growth in our five Employees are now able to connect and moxetumomab pasudotox growth platforms wirelessly across our sites.
Further Brilinta, diabetes, Emerging Markets, ITchanges are under way to improve 33 projects successfully progressed respiratory and Japan performance, and enhance the security to the next stage of development and privacy of our information including 14 projects entering first 8% growth in Emerging Markets human testing including 19% growth in China 15 projects withdrawn $1.8bn non-cash, non-Core, pre-tax impairment charge incurred as a result of Bydureon sales below commercial expectations Our year in brief 2013 January AstraZeneca and Moderna Cambridge Biomedical Campus September Changes to the Senior Executive Therapeutics announce exclusive in the UK selected as location AstraZeneca ranks in top 3% Team announced agreement to develop pioneering of new global R&D centre and in the sector in the Dow Jones Sustainability and World Indexes messenger RNA Therapeutics corporate headquarters March with a score of 85% Australia Federal Court AstraZeneca and Karolinska Top-line results for SAVOR-TIMI 53 holds Crestor patents invalid.
Institutet announce intention to cardiovascular outcomes trial Initiation of Phase III clinical programme for olaparib US litigation over Crestor create Integrated Translational of Onglyza patent settled Research Centre October July Announce strategy to Return June AstraZeneca and FibroGen agree Initiation of Phase III for selumetinib for advanced to Growth and Achieve Announce decision not to to collaborate to develop and Scientific Leadership, as well proceed with regulatory filings for commercialise roxadustat or metastatic non-small cell lungcancer as restructuring and investment fostamatinib in rheumatoid arthritis FG-4592 for anaemia in chronic in strategic R&D centres in the following top-line results from kidney disease and end-stage US, the UK and Sweden Phase III OSKIRA trials renal disease 4 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information Shareholder distributions Distributions to shareholders $m Dividend for 2013 2013 2012 2011 $ Pence SEK Payment date Dividends 3,461 3,665 3,764 First interim dividend 0.90 59.2 5.92 16 September 2013 1 2 3 Second interim dividend 1.90 116.8 12.41 24 March 2014 Share repurchases 2,635 6,015 Total 2.80 176.0 18.33 Total 3,461 6,300 9,779 1 T he share repurchase programme was suspended effective 1 October 2012.
2 Dividend per Ordinary Share $ S hare repurchases in 2012, net of proceeds from the issue of share capital equal to $429 million, were $2,206 million.
2013 2012 2011 3 S hare repurchases in 2011, net of proceeds from the issue of share capital equal to $409 million, were $5,606 million.
Dividend per Ordinary Share 2.80 2.80 2.80 Strategic R&D centres In 2013 we announced our intention to increase our proximity to bioscience clusters and co-locate around three strategic sites Gaithersburg, US Cambridge, UK Mlndal, Sweden Connections to National Institutes of Health Connections to the University of Cambridge Connections to Karolinska Institutet and and Johns Hopkins University and its world-class bioscience community Medicon Valley Acquisitions Over the past three years we have completed more than 150 major business development transactions.
In 2013, we announced the : AlphaCore a biotech company focused Omthera a specialty company working Spirogen a biotech company focused ona novel approach to CVMD onnew therapies for dyslipidaemia onantibody-drug conjugate technology foruse in oncology Amplimmune a biologics company Pearl Therapeutics a company focused developing novel therapeutics in cancer on respiratory disease Acquisition of global diabetes business immunology purchase of BMSs 50% interest in AstraZenecas and BMSs joint diabetes business See the Therapy Area Review from page 48 for more information.
2014 Benralizumab advances to November lipodystrophy, but does not Following performance below PhaseIII for severe asthma Announce plans to invest recommend for the treatment commercial expectations in $190million in a new facility to of partial lipodystrophy for the relation to Bydureon, incur a Marc Dunoyer appointed CFO produce Zoladex at our global proposed indication non-cash, non-Core, pre-tax and Executive Director on manufacturing site in Macclesfield impairment charge of SimonLowths departure from Announce top-line results from approximately $1.8 billion in the UK AstraZeneca Phase III monotherapy study January 2014 December of lesinurad in gout patients US Court of Appeals for the Fluenz Tetra is granted marketing FDA approves Farxiga in the US Federal Circuit reverses trial Announce agreement to for adults with Type 2 diabetes authorisation by the EC courtdecision that generic acquire BMSs 50% interest in EC approves Xigduo in the EU defendants do not infringe a FDA Advisory Committee AstraZenecas and BMSs joint patent protecting Pulmicort recommends metreleptin for the diabetes business for adults with Type 2 diabetes Respules in the US but affirms treatment of paediatric and adult that another patent is invalid patients with generalised AstraZeneca Annual Report and Form 20-F Information 2013 5
